To include your compound in the COVID-19 Resource Center, submit it here.

PPL acquires rights from Bristol-Myers

PPL Therapeutics (LSE:PTH) acquired exclusive global rights to BMY's

Read the full 93 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE